Neuromuscular Blocking Drug Global Market Report 2025

Description

A neuromuscular blocking drug is a medication that disrupts the transmission of nerve impulses to muscles, resulting in the temporary paralysis of skeletal muscles. These drugs function by either blocking the action of acetylcholine, a neurotransmitter, at the neuromuscular junction-where nerves and muscles communicate-or by mimicking acetylcholine and overstimulating the muscle receptor, causing it to become unresponsive. Neuromuscular blocking drugs are mainly used in medical settings, particularly during surgeries or other procedures, to facilitate intubation (the insertion of a breathing tube) and ensure muscle relaxation.

The primary types of neuromuscular blocking drugs are non-depolarizing agents and depolarizing agents. Non-depolarizing agents act by competing with acetylcholine at the neuromuscular junction, preventing muscle contraction. These drugs are available through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and serve a range of end users, such as hospitals, homecare, specialty clinics, and others.

The neuromuscular blocking drugs market research report is one of a series of new reports from The Business Research Company that provides neuromuscular blocking drugs market statistics, including neuromuscular blocking drugs industry global market size, regional shares, competitors with a neuromuscular blocking drugs market share, detailed neuromuscular blocking drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neuromuscular blocking drugs industry. This neuromuscular blocking drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuromuscular blocking drug market size has grown strongly in recent years. It will grow from $3.87 $ billion in 2024 to $4.08 $ billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased prevalence of conditions, increased awareness and training, increased healthcare spending, improved drug reversibility, and rise emphasis on patient safety.

The neuromuscular blocking drug market size is expected to see strong growth in the next few years. It will grow to $4.98 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to regulatory approvals, growth in outpatient and day surgeries, the expansion of medical tourism and strategic alliances, the growing prevalence of musculoskeletal disorders, and the increasing prevalence of surgical procedures. Major trends in the forecast period include the development of non-sedative formulations, the development of new NMBDs, advances in personalized medicine, the development of combination therapies, and patient-centric drug development.

The growing number of surgical procedures is expected to drive the expansion of the neuromuscular blocking drug market in the future. Surgical procedures are medical interventions that involve incisions, excisions, or other techniques to treat injuries, diseases, or conditions. This rise in surgical procedures is attributed to advancements in diagnostic tools, better access to healthcare, an increased focus on quality of life, and growing patient awareness and expectations. Neuromuscular blocking drugs are utilized in these procedures to induce muscle relaxation and aid in various surgical aspects. For example, in September 2023, a report by the American Society of Plastic Surgeons, a professional organization based in the US, revealed that in 2022, a total of 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States. As a result, the increasing frequency of surgical procedures is fueling the growth of the neuromuscular blocking drug market.

Major companies in the neuromuscular blocking drug market are expanding their product lines through strategic collaborations to enhance market reach and drive innovation in drug formulations and delivery methods. These collaborations involve partnerships that leverage shared resources and expertise to advance product development. For instance, in May 2022, BDR Pharma, an India-based pharmaceutical company, partnered with Varenyam Healthcare, another India-based pharmaceutical manufacturer, to launch Sugmadex. Sugmadex is a novel anesthesia drug that provides a safe, rapid, and complete reversal of neuromuscular block (NMB), including shallow, moderate, and deep NMB, thus effectively eliminating anesthesia effects. It addresses profound NMB and reduces post-operative respiratory complications, available in 2 ml and 5 ml single-dose vials, enhancing efficiency and patient safety.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals for an undisclosed amount. This acquisition aims to strengthen Biogen's rare disease portfolio by incorporating Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia, complementing its existing treatments for spinal muscular atrophy and amyotrophic lateral sclerosis. This move addresses unmet medical needs and drives growth in the market. Reata Pharmaceuticals is a US-based company specializing in rare neuromuscular blocking drugs.

Major companies operating in the neuromuscular blocking drug market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Bayer AG, Fresenius Kabi AG, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Baxter International Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, UCB Pharma S.A., Eisai Co Ltd., Ipsen S.A., B. Braun Melsungen AG, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals plc, Mylan N.V., Nippon Shinyaku Co Ltd., Sagent Pharmaceuticals Inc., Osmosis Inc., Cadila Healthcare Limited

North America was the largest region in the neuromuscular blocking drugmarket in 2023. The regions covered in the neuromuscular blocking drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuromuscular blocking drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuromuscular blocking drug market consists of sales of ganta curium, rapacuronium, alcuronium, tubocurarine, and metocurine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromuscular Blocking Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromuscular blocking drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromuscular blocking drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuromuscular blocking drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Non-Polarizing Agents; Depolarizing Agents
2) By Application: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Others Applications
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Non-Polarizing Agents: Benzylisoquinolines; Steroidal Agents; Long-Acting Agents; Intermediate-Acting Agents; Short-Acting Agents;
2) By Depolarizing Agents: Succinylcholine; Analogues of Succinylcholine; Rapid-Onset Agents; Short-Acting Agents; Intermediate-Acting Agents
Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; AbbVie Inc.; Bayer AG; Fresenius Kabi AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32090

1. Executive Summary

2. Neuromuscular Blocking Drug Market Characteristics

3. Neuromuscular Blocking Drug Market Trends And Strategies

4. Neuromuscular Blocking Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neuromuscular Blocking Drug Growth Analysis And Strategic Analysis Framework

5.1. Global Neuromuscular Blocking Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neuromuscular Blocking Drug Market Growth Rate Analysis
5.4. Global Neuromuscular Blocking Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neuromuscular Blocking Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neuromuscular Blocking Drug Total Addressable Market (TAM)

6. Neuromuscular Blocking Drug Market Segmentation

6.1. Global Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Polarizing Agents
Depolarizing Agents
6.2. Global Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Applications
6.3. Global Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.4. Global Neuromuscular Blocking Drug Market, Sub-Segmentation Of Non-Polarizing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Benzylisoquinolines
Steroidal Agents
Long-Acting Agents
Intermediate-Acting Agents
Short-Acting Agents
6.5. Global Neuromuscular Blocking Drug Market, Sub-Segmentation Of Depolarizing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Succinylcholine
Analogues of Succinylcholine
Rapid-Onset Agents
Short-Acting Agents
Intermediate-Acting Agents

7. Neuromuscular Blocking Drug Market Regional And Country Analysis

7.1. Global Neuromuscular Blocking Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neuromuscular Blocking Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromuscular Blocking Drug Market

8.1. Asia-Pacific Neuromuscular Blocking Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromuscular Blocking Drug Market

9.1. China Neuromuscular Blocking Drug Market Overview
9.2. China Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromuscular Blocking Drug Market

10.1. India Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromuscular Blocking Drug Market

11.1. Japan Neuromuscular Blocking Drug Market Overview
11.2. Japan Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromuscular Blocking Drug Market

12.1. Australia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromuscular Blocking Drug Market

13.1. Indonesia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromuscular Blocking Drug Market

14.1. South Korea Neuromuscular Blocking Drug Market Overview
14.2. South Korea Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromuscular Blocking Drug Market

15.1. Western Europe Neuromuscular Blocking Drug Market Overview
15.2. Western Europe Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromuscular Blocking Drug Market

16.1. UK Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromuscular Blocking Drug Market

17.1. Germany Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromuscular Blocking Drug Market

18.1. France Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromuscular Blocking Drug Market

19.1. Italy Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromuscular Blocking Drug Market

20.1. Spain Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromuscular Blocking Drug Market

21.1. Eastern Europe Neuromuscular Blocking Drug Market Overview
21.2. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromuscular Blocking Drug Market

22.1. Russia Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromuscular Blocking Drug Market

23.1. North America Neuromuscular Blocking Drug Market Overview
23.2. North America Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromuscular Blocking Drug Market

24.1. USA Neuromuscular Blocking Drug Market Overview
24.2. USA Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromuscular Blocking Drug Market

25.1. Canada Neuromuscular Blocking Drug Market Overview
25.2. Canada Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromuscular Blocking Drug Market

26.1. South America Neuromuscular Blocking Drug Market Overview
26.2. South America Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromuscular Blocking Drug Market

27.1. Brazil Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromuscular Blocking Drug Market

28.1. Middle East Neuromuscular Blocking Drug Market Overview
28.2. Middle East Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromuscular Blocking Drug Market

29.1. Africa Neuromuscular Blocking Drug Market Overview
29.2. Africa Neuromuscular Blocking Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neuromuscular Blocking Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neuromuscular Blocking Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromuscular Blocking Drug Market Competitive Landscape And Company Profiles

30.1. Neuromuscular Blocking Drug Market Competitive Landscape
30.2. Neuromuscular Blocking Drug Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Neuromuscular Blocking Drug Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. GlaxoSmithKline plc
31.4. Boehringer Ingelheim GmbH
31.5. Teva Pharmaceutical Industries Limited
31.6. Baxter International Inc.
31.7. Astellas Pharma Inc.
31.8. Daiichi Sankyo Company Limited
31.9. UCB Pharma S.A.
31.10. Eisai Co Ltd.
31.11. Ipsen S.A.
31.12. B. Braun Melsungen AG
31.13. Aurobindo Pharma Limited
31.14. Hikma Pharmaceuticals PLC
31.15. Mallinckrodt Pharmaceuticals plc

32. Global Neuromuscular Blocking Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromuscular Blocking Drug Market

34. Recent Developments In The Neuromuscular Blocking Drug Market

35. Neuromuscular Blocking Drug Market High Potential Countries, Segments and Strategies

35.1 Neuromuscular Blocking Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Neuromuscular Blocking Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Neuromuscular Blocking Drug Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer